2 results
Approved WMOCompleted
synopsis:Primary:• To assess the health related quality of life (HRQoL) through the MSQoL-54 scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months)Secondary:• To assess treatment…
Approved WMOCompleted
Primary objective: to investigate the effect of treatment with the SGLT-2 inhibitor dapagliflozin on the awareness of and counterregulatory hormone responses to hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia.…